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Abstract Bullous pemphigoid (BP) is a subepidermal skin
blistering disease characterized immunohistologically by
dermal-epidermal junction (DEJ) separation, an inXamma-
tory cell inWltrate in the upper dermis, and autoantibodies
targeted toward the hemidesmosomal proteins BP230 and
BP180. Development of an IgG passive transfer mouse
model of BP that reproduces these key features of human
BP has demonstrated that subepidermal blistering is initiated
by anti-BP180 antibodies and mediated by complement acti-
vation, mast cell degranulation, neutrophil inWltration, and
proteinase secretion. This model is not compatible with
study of human pathogenic antibodies, as the human and
murine antigenic epitopes are not cross-reactive. The devel-
opment of two novel humanized mouse models for the Wrst
time has enabled study of disease mechanisms caused by BP
autoantibodies, and presents an ideal in vivo system to test
novel therapeutic strategies for disease management.
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Etiology of bullous pemphigoid
In 1953, Lever [28] described bullous pemphigoid (BP) as
a subepidermal blistering disorder primarily seen in the eld-
erly. Lesional/perilesional skin of BP patients exhibits
detachment of the basal keratinocytes of the epidermis from
the dermis at the level of the lamina lucida [55], resulting in
tense, Xuid-Wlled vesicles. BP is both an inXammatory dis-
ease and an autoimmune disease, characterized by an
inXammatory inWltrate at the site of the dermal–epidermal
junction separation and by the deposition of autoantibodies
and complement components along the basement mem-
brane zone (BMZ).
A number of inXammatory cells are present in the upper
dermis and bullous cavity, including eosinophils (the pre-
dominant cell type), neutrophils, lymphocytes, and mono-
cytes/macrophages. Both intact and degranulating
eosinophils, neutrophils, and mast cells (MC) are found in
the dermis. Local activation of these cells may occur via the
multiple inXammatory mediators present in the lesional
skin and/or blister Xuids, including (a) granular proteins
derived from degranulated leukocytes, such as eosinophil
cationic protein (ECP), eosinophil major basic protein
(MBP), and neutrophil-derived myeloperoxidase (MPO) [1,
4, 8] and (b) chemoattractants and cytokines, such as C5a
fragments, histamine, leukotriene B4, interleukin-1, -2, -4,
5, -6, -8, -15, TNF-, IFN-, RANTES, and eotaxin [9, 10,
21, 22, 46, 47, 48, 58, 62]. Additionally, several proteinases
are found in BP blister Xuid, including plasmin, collage-
nase, elastase, and 92-kDa gelatinase [2, 14, 24, 27, 44, 45,
52, 57]. These proteolytic enzymes may play a crucial role
subepidermal blister formation in BP via their ability to
degrade extracellular matrix proteins.
BP patients generate a polyclonal repertoire of autoantibod-
ies that bind to the BMZ and activate complement, as well as
circulating autoantibodies [20]. These autoantibodies target
two major hemidesmosomal antigens of 230 kD (BP230 or
BPAG1) and 180 kD (BP180, BPAG2, or type XVII colla-
gen) [25, 40, 56, 57]. BP230, a component of the hemidesm-
osomal plaque, is an intracellular protein, while BP180 is a
type II transmembrane protein [19,  23,  56]. Like BP230,
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BP180’s amino-terminal portion localizes to the intracellular
hemidesmosomal plaque [15,  18, 19]. Its carboxyl-terminal
region extends into the extracellular milieu of the BMZ, mak-
ing it the preferred target for pathogenic BP autoantibodies.
This antigenic extracellular region consists of 15 collagen
domains separated from one another by non-collagen
sequences. The largest of these non-collagen domains is
referred to as NC16A. Epitope mapping studies indicate that
BP autoantibodies of IgE and IgG isotypes and IgG1 and IgG4
subclasses recognize multiple epitopes that cluster within
BP180 NC16A [3, 11, 16, 26, 63]. Serum levels of these auto-
antibodies are correlated with disease severity [11, 17, 49].
Most BP patients elicit a cell mediated autoimmune
response in addition to the humoral response described.
Autoreactive CD4+ T lymphocytes recognize epitopes
within the extracellular region of BP180, primarily in the
NC16A domain [5, 29]. These T cells express memory cell
surface markers and exhibit a Th1/Th2 mixed cytokine pro-
Wle. These studies suggest that BP is a T and B cell-depen-
dent and antibody-mediated skin autoimmune disease.
Development of murine IgG passive transfer 
model of BP
The strong correlation between BP disease severity and
serum BP180-speciWc autoantibody levels suggests that BP
blister formation is mediated by autoantibodies. Early
attempts to demonstrate the pathogenicity of patient auto-
antibodies via a passive transfer mouse model were unsuc-
cessful because BP autoantibodies that react with an
immunodominant and potentially pathogenic epitope in
BP180-NC16A fail to cross-react with the murine form of
this autoantigen (mBP180 NC14A) [30]. In 1993, Liu et al.
[30] devised a strategy to overcome this diYculty and gen-
erated rabbit polyclonal antibodies raised against a cloned
segment of mBP180 NC14A and passively transferred the
puriWed rabbit anti-mBP180 IgG into neonatal BALB/c
mice. The injected animals developed a disease that exhib-
ited the following hallmarks of human BP: (a) clinical skin
lesions; (b) in vivo deposition of rabbit IgG and mouse C3
at the basement membrane by direct IF; (c) dermal-epider-
mal separation and an extensive inXammatory cell inWltra-
tion by H&E staining [30]. This inWltrate includes
neutrophils, lymphocytes, and monocytes/macrophages,
with neutrophils being the predominant cells [7, 30].
Immunopathogenesis of experimental BP in the murine 
model
Development of an in vivo system to study an experimental
BP model has allowed for great progress in deWning the
etiopathogenesis of disease. SpeciWcally, the roles of patho-
genic antibodies, the complement system, inXammatory
cells, and proteolytic enzymes have all been elucidated in
the context of the murine IgG passive transfer model.
Injection of anti-mBP180 IgG initiated subepidermal
blister formation, and the levels of circulating anti-mBP180
antibodies completely determine disease onset and severity
[30, 34]. Epitope mapping studies demonstrated that patho-
genic anti-BP180 antibodies recognize a 9–12 amino acid
stretch within the murine BP180 NC14A region of the anti-
gen [31]. This epitope overlaps the region of the human
BP180 NC16A that contains the immunodominant epitopes
recognized by human BP autoantibodies, supporting the
relevance of this murine system as a model for human dis-
ease.
Using mice deWcient in diVerent inXammatory cell types,
it has been demonstrated that mast cells, macrophages, and
neutrophils, but not T and B lymphocytes, play a direct role
in subepidermal blistering in experimental BP [7]. Anti-
mBP180 autoantibodies trigger skin blistering in wild-type
mice and mice deWcient in T, B, or both T and B cells, but
fail to induce lesions in mice deWcient in mast cells, macro-
phages, or neutrophils. QuantiWcation of disease severity in
these mice demonstrated that mast cells and neutrophils
play a key role in experimental BP.
Autoantibodies bind to basement membrane antigens
and activate complement in human BP. In the rabbit anti-
mBP180 IgG-induced BP, complement activation is abso-
lutely required. Both BALB/c mice depleted of comple-
ment (by pretreatment with cobra venom) and C5-deWcient
mice are resistant to experimental BP, and reconstitution of
the C5-deWcient mice with C5a restores susceptibility [32].
F(ab’)2 fragments generated from the pathogenic anti-
mBP180 IgG cannot induce subepidermal blisters in C5-
suYcient mice [32]. Mice deWcient in complement compo-
nent C4 (speciWc for the classical and lectin pathways), but
not in factor B (speciWc for the alternative pathway), are
resistant to BP [41]. Wild-type mice depleted of comple-
ment component C1q (speciWc for the classical pathway)
fail to develop BP skin lesions when injected with patho-
genic IgG [41]. These data suggest that the classical path-
way of the complement activation plays a major role in
development of disease, namely through the generation of
C5a that in turn activates MCs [6].
Mice injected with pathogenic anti-mBP180 antibodies
exhibit extensive MC degranulation in the lesional skin,
similar to that observed in human BP [6, 59]. MC-deWcient
mice are resistant to experimental BP, but reconstitution of
these mice with MCs restores their susceptibility to disease.
MC activation precedes neutrophil inWltration, and either
the absence of MCs or the inhibition of MC degranulation pre-
vents neutrophil inWltration and blister formation. However,
MC-deWcient mice reconstituted locally with neutrophils,Arch Dermatol Res (2007) 299:417–422 419
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or injected locally with neutrophil chemoattractants IL-8 or
TNF- form blisters in response to anti-mBP180 IgG.
These results suggest that mast cells release proinXamma-
tory cytokines critical for neutrophil recruitment [6].
Experimental BP requires neutrophil inWltration, and
there is a direct correlation between disease severity and
number of inWltrating neutrophils [33]. Depletion of neutro-
phils, or disruption of the events upstream of neutrophil
inWltration (complement activation and MC degranulation),
renders mice resistant to BP blister formation. However,
complement system and MC deWciencies only confer pro-
tection from the pathogenic eVects of BP180 autoantibodies
if neutrophil inWltration is blocked as a consequence; that
is, complement activation and MC degranulation are only
critical to disease progression in their roles of neutrophil
recruitment. This suggests that inWltrating neutrophils are
the cells that directly cause tissue injury in the dermal–epi-
dermal junction, leading to BP skin blisters.
Upon activation through molecular interactions between
the FcIIIR on the neutrophil cell surface and the Fc portion
of pathogenic anti-mBP180 IgG [61], inWltrating neutro-
phils secrete proteolytic enzymes known to degrade the
extracellular matrix, including neutrophil elastase (NE) and
gelatinase B (GB). A deWcit of either of these two enzymes
blocks blister formation in mice [35, 36]. In vitro, although
both GB and NE are capable of degrading the recombinant
BP180 protein, only NE produces DEJ separation when
incubated with skin sections [36, 52]. In vivo, the degrada-
tion of BP180 depends on NE activity. Taken together,
these Wndings suggest that GB acts upstream of NE. Spe-
ciWcally, GB proteolytically inactivates the physiological
inhibitor of NE (1-proteinase inhibitor), which allows for
unmitigated NE cleavage of extracellular matrix proteins
(including BP180), resulting in DEJ separation [37].
Development of the humanized murine passive transfer 
model
While the rabbit anti-mBP180 IgG passive transfer model
has provided invaluable insight to the key steps in BP dis-
ease development, it does not allow for experimentation
with BP autoantibodies isolated from human clinical sam-
ples. A second animal model, in which rabbit antibodies
directed against the extracellular domain of hamster BP180
(NC16A region) are transferred into neonatal hamsters, also
lacks cross-reactivity with antibodies directed against
human BP180 [59]. To assess the pathogenicity of human
anti-BP180 autoantibodies, we generated a novel mouse
strain in which the murine BP180NC14A was replaced
with the homologous human BP180NC16A epitope cluster
region [38]. The humanized NC16A (NC16+/+) mice
injected with anti-BP180NC16A autoantibodies develop
BP, and the disease development depends on complement,
mast cells and neutrophils (Fig. 1).
Using the NC16A+/+ mice and BP patients’ sera, we
mapped the pathogenic epitope of BP180 in vivo [39]. IgG
passive transfer experiments identiWed one pathogenic epi-
tope (referred to as BP180NC16A2.5). BP180NC16A2.5-
speciWc autoantibodies induced subepidermal blisters in the
NC16A+/+ mice, and these blisters were blocked by pre-
treatment with recombinant BP180NC16A2.5. We also
found that the NC16A2.5 pretreated mice had signiWcantly
reduced levels of BMZ-bound and circulating pathogenic
Fig. 1 Proposed mechanism of subepidermal blister formation in
humanized NC16A mouse model of BP. Subepidermal blistering is an
inXammatory process involved in following steps: a anti-BP180 auto-
antibodies are injected into NC16A mice; b pathogenic antibodies bind
to the pathogenic epitope of BP180 antigen in basal keratinocytes
(BK); c the molecular interaction between BP180 antigen and anti-
BP180 IgG activates the complement system (C) as evidenced by
BMZ deposition of mouse C3; d C activation products C3a and C5a
cause mast cells (MC) to degranulate; e MC activation leads to neutro-
phil (PMN) recruitment; f inWltrating PMNs bind to the BP180-anti-
BP180 immune complex via the molecular interaction between Fc
receptors on neutrophils and the Fc domain of anti-BP180 IgG. Acti-
vated PMNs release proteolytic enzymes; g proteolytic enzymes de-
grade BP180 and other extracellular matrix proteins, leading to
dermal–epidermal junction separation; h pathogenic antibody-injected
mice develop clinical blisters420 Arch Dermatol Res (2007) 299:417–422
123
antibodies and showed reduced complement activation,
mast cell degranulation and neutrophil inWltration. These
results suggest that targeting the pathogenic epitope speciW-
cally could be a new therapeutic strategy to treat BP.
A second humanized animal model has been developed
by Nishie et al. [42, 43] that replaces the mouse BP180
(COL17) with the human analogue. Upon injection of
human anti-BP180 autoantibodies, these mice reproduce
the DEJ separation at the lamina lucida, the deposition of
human IgG along the DEJ, and an inXammatory cell inWl-
trate consisting of neutrophils and eosinophils seen in
human disease. The pathogenic eVects of the autoantibody
injection are ablated by pretreatment with a 77-amino acid
peptide fragment of COL17 NC16A, referred to as R1.
These studies further support the therapeutic potential of
employing decoy peptides to block the pathogenic epitope.
Relevance of murine and humanized passive transfer 
models to human BP
Both in vitro and in vivo data demonstrate that BP180 is the
target for pathogenic autoantibodies in BP (Table 1). While
clinical human BP and experimental murine and humanized
murine BP closely mimic each other at the clinical, histo-
logical, and immunological levels, the IgG passive transfer
models do not reXect the large number of eosinophils typi-
cally found in the inXammatory inWltrate of human BP
lesional skin. Some patients do exhibit neutrophil-rich pem-
phigoid, indicating that the neutrophil-mediated blistering
observed in these mouse models may be one of several dis-
ease mechanisms that contribute to the formation and per-
sistence of subepidermal blisters. The presence of a
neutrophil-rich inXammatory inWltrate in the two human-
ized mouse models, as well as in the aforementioned ham-
ster model, lend credence to a neutrophil-mediated disease
mechanism. Furthermore, Wndings that in vitro DEJ separa-
tion induced by human BP autoantibodies speciWc for
BP180NC16A depends on neutrophils [51] and neutrophil-
derived elastase and gelatinase B [50], and that BP180 deg-
radation by human BP blister Xuid depends on neutrophil
elastase activity [57] support this theory. Taken together,
these Wndings strongly suggest that like the IgG passive
transfer model of BP, neutrophils may be responsible for
subepidermal blister formation in human BP, at least in
those patients who show neutrophil inWltration in their
lesional/perilesional skin. The humanized mouse models do
not yet oVer insight to an eosinophil-mediated mechanism
of disease progression, leaving the role of these inXamma-
tory cells, if there is any, yet to be discovered. It is possible
that these established mouse models, without additional
experimental manipulations, may not be able to fully dupli-
cate human BP pathology related to eosinophil inWltration;
therefore, they may not be appropriate to study the role of
eosinophils in BP.
Zone et al. [64] reported that IgE hybridoma to LABD97
antigen, a component of the shed ectodomain of BP180,
when injected subcutaneously in SCID mice with engrafted
human skin, induced eosinophil inWltration and histological
blisters in engrafted human skin. Fairley et al. [12] also
reported that total IgE isolated from BP sera, when injected
into human skin grafted onto athymic nude mice, triggered
a dermal inWltrate composed of neutrophils, eosinophils,
and histological separation of the epidermis from the der-
mis. These Wndings implicate eosinophils in BP; however, a
direct link between eosinophil recruitment and blistering in
these human skin graft models needs to be established.
Conclusions
The murine IgG passive transfer model of BP developed by
Liu et al. [30] has provided an invaluable tool for the dis-
section of the mechanism of disease progression. The
development of humanized murine models of BP now pro-
vides unprecedented insight to the pathogenic role of the
autoantibodies that mediate disease. Initial observations
with these humanized models indicate that humanized
mouse BP exhibits phenotypic and immunological similari-
ties with murine and human BP. Additionally, these
humanized models enabled the Wrst identiWcation of patho-
genic epitopes in human disease. Blocking of the patho-
genic epitope with decoy peptides, if they do not enhance
the autoimmune responses, presents a novel clinical thera-
peutic strategy that may be very eVective in abolishing the
pathogenic eVects of disease.
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